Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cresco Labs Inc C.CL

Alternate Symbol(s):  CRLBF

Cresco Labs Inc. is an integrated multi-state cannabis operator in the United States. The Company is licensed to cultivate, manufacture, and sell retail and medical cannabis products primarily through Sunnyside, Cresco Labs’ national dispensary brand, and third-party retail stores. Its family brands include Cresco, High Supply, Good News, Wonder Wellness Co., FloraCal Farms, Remedi and Mindy’s. Its portfolio consists of over 400 products. The Company's products are sold in over 1,600 dispensaries across the country. Its Cresco offers consistent strains, available in a variety of product forms at dispensaries and retail locations nationwide. Its High Supply lab-tested; and available in vape carts, vape pens, flower, popcorn, shake, shorties and concentrates. Its Remedi products provide a consistent and trusted alternative to traditional pharmaceuticals like opioids. Its Mindy’s offers dosed edibles created by James Beard. It is the wholesaler of branded cannabis products.


CSE:CL - Post by User

Post by kijijion Sep 14, 2022 3:31pm
161 Views
Post# 34962609

U.S. Cannabis Sales Expected to Reach $42 Billion by 2026

U.S. Cannabis Sales Expected to Reach $42 Billion by 2026
Cannabinoid-industry research firm BDSA releasing updated market forecast
on Sep. 13, 2022

LOUISVILLE, Colo. — Cannabis sales will grow from $25 billion in 2021 to $42 billion in 2026 in the United States, according to BDSA’s latest prediction.
 
The Louisville, Colo.-based cannabinoid-industry research firm expects global cannabis sales to be a $57 billion market by 2026 globally. It shared these findings in its updated cannabis market forecast, a five-year rolling global forecast by country, state, province channel and category. 
 
Cannabis sales in the United States also grew in 2022, despite an inflationary environment and concerns about a recession that dampened consumer spending, BDSA said. By the end of the year, U.S. cannabis sales will reach $27 billion, a 7% increase from 2021, according to the firm.

Illinois is expected to bring in $2 billion in cannabis sales in 2022—up 14% from 2021 sales. And newer markets like New jersey and New York represent an expansion of legal cannabis access to about 22 million adults, BDSA said.
 
BDSA helps businesses improve revenues, reduce innovation risk and prioritize market expansion with accurate and actionable cannabis market intelligence, consumer research and advisory services. The company provides a holistic understanding of the cannabis market by generating insights from point-of-sale (POS) data, wholesale data, consumer research and market forecasts.

<< Previous
Bullboard Posts
Next >>